Oppenheimer analyst Suraj Kalia lowered the firm’s price target on GE HealthCare (GEHC) to $85 from $89 and keeps an Outperform rating on the shares following quarterly results. The firm remains constructive long-term given GE’s ecosystem and multiple levers of growth, though China, tariffs/ macro pressures remain overhangs.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare price target lowered to $65 from $80 at Citi
- GE HealthCare price target lowered to $78 from $87 at Barclays
- GE HealthCare downgraded to Neutral from Buy at Goldman Sachs
- GE HealthCare Earnings Call: Growth Holds, Margins Squeezed
- GE Healthcare Kept at Hold as Analyst Cuts Price Target to $65 on Margin Pressure and Execution Risks